Occurrence and current frequency of CTX-M-type β-lactamases from a regional hospital in the South West of England [12]

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 4, 2007, Pages 815-816

  Tarrant, F ^a   MacGowan, A P ^b   Walsh, T R ^c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

lactam resistance; lactamases; Extended spectrum; Mobile genes

Indexed keywords

BETA LACTAMASE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; OLIGONUCLEOTIDE;

BACTERIAL CHROMOSOME; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA FLANKING REGION; DNA SEQUENCE; ENTEROBACTERIACEAE; ENVIRONMENTAL FACTOR; ESCHERICHIA COLI; GENE INSERTION; GENETIC ANALYSIS; GENETIC CODE; GENETIC SCREENING; GENOTYPE; HOSPITAL; HUMAN; KLEBSIELLA PNEUMONIAE; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PLASMID; POLYMERASE CHAIN REACTION; REPLICON; SALMONELLA; UNITED KINGDOM; URINARY TRACT; ANTIBIOTIC RESISTANCE; CROSS INFECTION; DRUG EFFECT; ENTEROBACTER INFECTION; ENZYMOLOGY; METABOLISM; MICROBIOLOGY;

BETA-LACTAMASES; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ENGLAND; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENOTYPE; HUMANS;

EID: 34249990736     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl559     Document Type: Letter

References (9)

1. Hopkins KL, Batchelor MJ, Liebana E et al. Characterisation of CTX-M and AmpC genes in human isolates of Escherichia coli identified between 1995 and 2003 in England and Wales. Int J Antimicrob Agents 2006; 28: 180-92.
2. Woodford N, Kaufmann ME, Karisik E et al. Molecular epidemiology of multi-resistant Escherichia coli isolates from community-onset urinary tract infections in Cornwall, England. J Antimicrob Chemother 2007; 59: 106-9.
3. Livermore DM, Hawkey PM. CTX-M: Changing the face of ESBLs in the UK. J Antimicrob Chemother 2005; 56: 451-4.
4. Woodford N, Ward ME, Kaufmann ME et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother 2004; 54: 735-43.
5. CTX-M in Escherichia coli. Antimicrob Agents Chemother 2005; 49: 447-50.
6. Andrews J. BSAC standardized disc susceptibility testing method (version 5). J Antimicrob Chemother 2006; 58: 511-29.
7. Munday CJ, Whitehead GM, Todd NJ et al. Predominance and genetic diversity of community- and hospital-acquired CTX-M extended spectrum β-lactamases in York, UK. J Antimicrob Chemother 2004; 54: 628-33.
8. Karim A, Poirel L, Nagarajan S et al. Plasmid-mediated extended-spectrum β-lactamase (CTX-M-3-like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol Lett 2001; 201: 237-41.
9. Toleman MA, Beidenbach D, Jones RN et al. Molecular characterisation of β-lactamases from Escherichia coli isolated from a multi-centre trial in India: Benchmark report from the MYSTIC program. In: Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract C2-1872, p. 114. American Society for Microbiology, Washington, DC, USA.